GV20 Therapeutics (https://gv20tx.com) was incorporated in 2016 with sites in Cambridge, USA, and Shanghai, China. The company utilizes high throughput functional genomics and AI approaches to identify novel cancer immunology drug targets, and discover and develop effective antibody drugs in cancer. GV20's proprietary antibody drug discovery engine has helped establish a solid portfolio of immuno-oncology antibody drug candidates for cancer treatment.
Company Details
- Employees
- 22
- Founded
- -
- Address
- 237 Putnam Ave, Cambridge,massachusetts 02139,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://gv20tx.com
- Keywords
- AI, Antibody, Immunotherapy, Genomics.
- HQ
- Cambridge, Massachusetts
Gv20 Therapeutics Questions
Gv20 Therapeutics's website is https://gv20tx.com
Gv20 Therapeutics's LinkedIn profile is https://www.linkedin.com/company/gv20tx
Gv20 Therapeutics has
22 employees.
View email and phone details for 22
employees at Gv20 Therapeutics.
Gv20 Therapeutics's industry is
Biotechnology Research
Gv20 Therapeutics's top competitors are
Curie.bio,
D2m Biotherapeutics,
Modex Therapeutics Inc,
Generate:biomedicines,
Marengo Therapeutics,
Labshares,
Strand Therapeutics,
Alloy Therapeutics, Inc.,
Lifemine Therapeutics,
Cellino.
Gv20 Therapeutics's categories are Biotechnology Research
Gv20 Therapeutics's founding year is 2016
